Science & Technology
Science and Technology
Science and Technology
Fri, July 31, 2009
Thu, July 30, 2009 CDEX Inc.: ValiMed Pay-Per-Use Pricing Program Positively Received by Hospitals to Enhance Patient Safety and Reduce Narcotic D
TUCSON, AZ--(Marketwire - July 30, 2009) - CDEX Inc. (
"By also offering a Pay-Per-Use Pricing as an alternative to capital purchase, CDEX positions its ValiMed technology to be in reach of every hospital no matter size or specialty," said Greg Firmbach, Senior Vice President of CDEX. "Pay-Per-Use pricing is an all inclusive turnkey approach to placing life-saving technology with equipment, supplies and service all for around $2.50 per test. The reaction in the marketplace has been very positive as hospitals are now reviewing the integration of multiple ValiMed units into their medication safety programs for only the cost of supplies, an operating budget item."
ValiMed is used to validate "The Right Drug at The Right Dose" when high-risk liquid medications are compounded in a pharmacy setting and also as a verification program to reduce the diversion of return narcotics in hospitals and other healthcare facilities. CDEX expects demand to continue to build as the health system pharmacists, patient safety agencies and associations and the Joint Commission become more aware of the availability of ValiMed at these prices.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at [ mphilips@cdex-inc.com ].
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements
